CLAIMS

1. A method of treating psoriasis in a subject comprising administering to the subject an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject maintains at least a PASI 75 response for a first extended period following initial administration of the antibody, or antigen-binding portion thereof, wherein the subject exhibits a loss of response following discontinuation of administration of the antibody, or antigen-binding portion thereof, and wherein the subject maintains at least a PASI 75 response for a second extended period following re-administration of the antibody, or antigen-binding portion thereof, thereby treating psoriasis in the subject.

2. The method of claim 1, wherein the first extended period is at least about 12 weeks.

3. The method of claim 1, wherein administration of the antibody is discontinued for at least about 12 weeks.

4. The method of claim 1, wherein the second extended period is at least about 12 weeks.

5. The method of claim 1, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

6. The method of claim 1, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

7. The method of claim 1, wherein the antibody, or antigen-binding portion thereof, is administered in a single dose.

8. The method of claim 1, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

9. The method of claim 1, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

10. The method of claim 1, wherein the psoriasis is chronic psoriasis.

11. A method of treating psoriasis in a subject comprising administering to the subject a single dose of an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein at least one pharmacokinetic characteristic selected from the group consisting of a half-life of at least about 3 days, a T_{max} of less than or equal to about 4 days, and a bioavailability of at least about 40% is achieved following administration of the antibody, or antigen-binding portion thereof.

12. The method of claim 11, wherein a half life of at least about 8 days is achieved.

13. The method of claim 11, wherein a T_{max} of less than or equal to about 3 days is achieved.

14. The method of claim 11, wherein a bioavailability of at least about 60% is achieved.

15. The method of claim 11, wherein the antibody is administered via intravenous injection.

16. The method of claim 11, wherein the antibody is administered via subcutaneous injection.

17. The method of claim 11, wherein the single dose is between about 0.1 and about 5.0 mg/kg of the antibody, or antigen-binding portion thereof.

18. A method of treating psoriasis in a subject comprising administering to the subject an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject maintains at least a PASI 75 response for a first extended period following initial administration of the antibody, or antigen-binding portion thereof, wherein the subject exhibits a loss of response following discontinuation of administration of the antibody, or antigen-binding portion thereof, and wherein the subject maintains at least a PASI 50 response for a second extended period following re-administration of the antibody, or antigen-binding portion thereof, thereby treating psoriasis in the subject.

19. The method of claim 18, wherein the first extended period is at least about 12 weeks.

20. The method of claim 18, wherein administration of the antibody is discontinued for at least about 12 weeks.

21. The method of claim 18, wherein the second extended period is at least about 12 weeks.

22. The method of claim 18, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

23. The method of claim 18, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

24. The method of claim 18, wherein the antibody, or antigen-binding portion thereof, is administered in a single dose.

25. The method of claim 18, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

26. The method of claim 18, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

27. The method of claim 18, wherein the psoriasis is chronic psoriasis.

28. A method of treating psoriasis in a subject comprising administering to the subject an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject maintains at least a PASI 75 response for a first extended period following initial administration of the antibody, or antigen-binding portion thereof, wherein the subject exhibits a loss of response following discontinuation of administration of the antibody, or antigen-binding portion thereof, and wherein the subject maintains a clear or minimal PGA score for a second extended period following re-administration of the antibody, or antigen-binding portion thereof, thereby treating psoriasis in the subject.

29. The method of claim 28, wherein the first extended period is at least about 12 weeks.

30. The method of claim 28, wherein administration of the antibody is discontinued for at least about 12 weeks.

31. The method of claim 28, wherein the second extended period is at least about 12 weeks.

32. The method of claim 28, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

33. The method of claim 28, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

34. The method of claim 28, wherein the antibody, or antigen-binding portion thereof, is administered in a single dose.

35. The method of claim 28, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

36. The method of claim 28, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

37. The method of claim 28, wherein the psoriasis is chronic psoriasis.

38. A method of treating psoriasis in a subject comprising administering to the subject a single dose of an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein at least one pharmacokinetic characteristic selected from the group consisting of a maximum serum concentration (C_{max}) of between about 0.15 and about 150 µg/mL, and an area under the serum concentration-time curve (AUC) of between about 80 and about 13,000 µg x hr/mL, is achieved following administration of the antibody, or antigen-binding portion thereof.

39. The method of claim 38, wherein the antibody is administered via intravenous injection.

40. The method of claim 39, wherein the C_{max} is between about 1 and about 150 µg/mL.

41. The method of claim 39, wherein the AUC is between about 145 and about 13,000 µg x hr/mL.

42. The method of claim 38, wherein the antibody is administered via subcutaneous injection.

43. The method of claim 42, wherein the C_{max} is between about 0.15 and about 20 µg/mL.

44. The method of claim 42, wherein the AUC is between about 80 and about 5,000 µg x hr/mL.

45. The method of claim 38, wherein the single dose is between about 0.1 and about 5.0 mg/kg of the antibody, or antigen-binding portion thereof.

46. A method of treating psoriasis in a subject comprising administering to the subject a single dose of an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein at least one pharmacokinetic characteristic selected from the group consisting of a clearance (CL) of between about 30 and about 600 mL/hr, and a volume of distribution (Vz) of between about 8 and about 11 L is achieved following intravenous administration of the antibody, or antigen-binding portion thereof.

47. A method of treating psoriasis in a subject comprising administering to the subject a single dose of an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein at least one pharmacokinetic characteristic selected from the group consisting of an apparent clearance (CL/F) of between about 90 and about 250 mL/hr, and an apparent volume of distribution (V/F) of between about 23 and about 67 L is achieved following subcutaneous administration of the antibody, or antigen-binding portion thereof.

48. The method of claim 46 or 47, wherein the single dose is between about 0.1 and about 5.0 mg/kg of the antibody, or antigen-binding portion thereof.

49. A method of treating psoriasis in a subject comprising administering to the subject an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject exhibits a

PASI 75 response following initial administration of the antibody, or antigen-binding portion thereof, wherein the subject exhibits a loss of response following discontinuation of administration of the antibody, or antigen-binding portion thereof, and wherein the subject exhibits at least a PASI 75 response by about 25 days following re-administration of the antibody, or antigen-binding portion thereof, thereby treating psoriasis in the subject.

50. The method of claim 49, wherein the subject exhibits at least a PASI 75 response by about 50 days following re-administration of the antibody, or antigen-binding portion thereof.

51. The method of claim 49, wherein the subject exhibits at least a PASI 75 response by about 60 days following re-administration of the antibody, or antigen-binding portion thereof.

52. The method of claim 49, wherein initial administration of the antibody is for at least about 12 weeks.

53. The method of claim 49, wherein administration of the antibody is discontinued for at least about 8 weeks.

54. The method of claim 49, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

55. The method of claim 49, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

56. The method of claim 49, wherein the antibody, or antigen-binding portion thereof, is administered in a single dose.

57. The method of claim 49, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

58. The method of claim 49, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

59. The method of claim 49, wherein the psoriasis is chronic psoriasis.

60. A method of treating psoriasis in a subject comprising administering to the subject an antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23, wherein the subject exhibits a PASI 75 response following initial administration of the antibody, or antigen-binding portion thereof, wherein the subject exhibits a loss of response by about 60 days following discontinuation of administration of the antibody, or antigen-binding portion thereof, and wherein the subject achieves a PASI 75 response following re-administration of the antibody, or antigen-binding portion thereof, thereby treating psoriasis in the subject.

61. The method of claim 60, wherein the subject exhibits a loss of response by about 120 days following discontinuation of administration of the antibody, or antigen-binding portion thereof.

62. The method of claim 60, wherein the subject exhibits a loss of response by about 180 days following discontinuation of administration of the antibody, or antigen-binding portion thereof.

63. The method of claim 60, wherein initial administration of the antibody is for at least about 12 weeks.

64. The method of claim 60, wherein the antibody, or antigen-binding portion thereof, is administered biweekly.

65 The method of claim 60, wherein the antibody, or antigen-binding portion thereof, is administered weekly.

66. The method of claim 60, wherein the antibody, or antigen-binding portion thereof, is administered in a single dose.

67. The method of claim 60, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 200 mg.

68. The method of claim 60, wherein the antibody, or antigen-binding portion thereof, is administered in a dose of about 100 mg.

69. The method of claim 60, wherein the psoriasis is chronic psoriasis.

CLAIMS

1. An antibody, or antigen-binding portion thereof, which is capable of binding to an epitope of the p40 subunit of IL-12 and/or IL-23 for use in treating psoriasis in a subject by administering to the subject the antibody, or antigen-binding portion thereof,

wherein the subject exhibits at least a PASI 75 response by week 12 of a first extended period following initial administration of the antibody, or antigen-binding portion thereof,

wherein the subject exhibits decrease in PASI score to less than PASI 50 following discontinuation of administration of the antibody, or antigen-binding portion thereof, and

wherein the subject exhibits at least a PASI 50 response following re-administration of the antibody, or antigen-binding portion thereof, by week 12 of a second extended period following re-administration,

thereby treating psoriasis in the subject.

2. The antibody, or antigen-binding portion thereof, according to claim 1, wherein the antibody, or antigen-binding portion thereof, is administered or re-administered biweekly.

3. The antibody, or antigen-binding portion thereof, according to claim 1, wherein the antibody, or antigen-binding portion thereof, is administered or re-administered weekly.

4. The antibody, or antigen-binding portion thereof, according to claim 1, wherein the antibody, or antigen-binding portion thereof, is administered or re-administered in a single dose.

5. The antibody, or antigen-binding portion thereof, according to claim 1, wherein the antibody, or antigen -binding portion thereof, is administered or re-administered in a dose of about 200 mg.

6. The antibody, or antigen-binding portion thereof, according to claim 1, wherein the antibody, or antigen-binding portion thereof, is administered or re-administered in a dose of about 100 mg.

7. The antibody, or antigen-binding portion thereof, according to claim 1, wherein the psoriasis is chronic psoriasis.

8. The antibody, or antigen-binding portion thereof, according to claim 1, wherein at least a PASI 75 response is achieved by week 12 of the second extended period.